CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Optimind Pharma Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Optimind Pharma Corp
77 King Street West - Suite 3000
TORONTO, ON  M5K 1G8  Canada Ticker: OMNDOMND
Business Summary
Optimind Pharma Corp. is a Canada-based emerging provider of psychedelic therapies for the masses. The Company helps people suffering from post-traumatic stress disorder (PTSD), anxiety, depression and other mental illnesses and disabilities by providing ketamine-assisted-treatment and other psychedelic-enhanced-psychotherapy modalities. The Company also partnered with developers of psilocybin-associated treatments and products to further expand its treatment and program offerings. Its treatment programs are designed based on scientific research and specific modalities used in many different therapeutic practices. Each treatment program combines the use of psychedelic medicine with therapeutic processing and integration. It has two different types of treatments. Monotherapy and assisted therapy, all based on a Ketamine capsule. The effects are felt about 30 minutes after, and within two hours of taking the medicine, cognition is resorted to normal.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
8/31/20242/29/2024Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
8063 Psychiatric hospitals

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Timothy M.Elliott 10/1/2008 10/1/2008
President, Chief Executive Officer, Director Norman W.Holton 10/30/2008 10/30/2008
Director Jock M.Graham 10/1/2008 10/1/2008
3 additional Officers and Directors records available in full report.

Business Names
Business Name
LNE
LNE.H
Loon Colombia Limited
4 additional Business Names available in full report.

General Information
Outstanding Shares: 109,788,491 (As of 8/31/2024)
Stock Exchange: CNQ


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, December 2, 2024